| Primary |
| Breast Cancer |
43.0% |
| Breast Cancer Metastatic |
31.0% |
| Product Used For Unknown Indication |
7.7% |
| Drug Use For Unknown Indication |
3.5% |
| Breast Cancer Stage Iv |
1.9% |
| Pain |
1.9% |
| Prophylaxis |
1.5% |
| Breast Neoplasm |
1.2% |
| Hypertension |
1.0% |
| Metastases To Central Nervous System |
1.0% |
| Diuretic Therapy |
0.8% |
| Metastases To Bone |
0.8% |
| Back Pain |
0.6% |
| Her-2 Positive Breast Cancer |
0.6% |
| Left Ventricular Failure |
0.6% |
| Peptic Ulcer |
0.6% |
| Prophylaxis Of Nausea And Vomiting |
0.6% |
| Thrombosis |
0.6% |
| Arrhythmia |
0.4% |
| Cervix Carcinoma Recurrent |
0.4% |
|
| Vomiting |
13.0% |
| Death |
8.6% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
8.0% |
| Skin Toxicity |
6.8% |
| Stomatitis |
6.8% |
| Rash |
5.6% |
| Diarrhoea |
4.9% |
| Jaundice |
4.9% |
| Renal Failure Acute |
4.9% |
| Metastases To Liver |
4.3% |
| Transaminases Increased |
4.3% |
| Nausea |
3.7% |
| Skin Fissures |
3.7% |
| Weight Decreased |
3.7% |
| Pulmonary Embolism |
3.1% |
| Staphylococcal Infection |
3.1% |
| Thrombosis |
3.1% |
| Hepatotoxicity |
2.5% |
| Mucosal Inflammation |
2.5% |
| Oedema Peripheral |
2.5% |
|
| Secondary |
| Product Used For Unknown Indication |
54.0% |
| Breast Cancer Metastatic |
22.7% |
| Breast Cancer |
15.6% |
| Metastatic Neoplasm |
2.4% |
| Nausea |
2.4% |
| Breast Cancer Stage Iv |
1.2% |
| Drug Use For Unknown Indication |
0.6% |
| Diarrhoea |
0.3% |
| Hypertension |
0.3% |
| Lymphadenopathy |
0.3% |
| Prophylaxis |
0.3% |
|
| Vulvovaginal Dryness |
18.3% |
| Tumour Marker Increased |
10.0% |
| Metastases To Liver |
8.3% |
| Diarrhoea |
6.7% |
| Disease Progression |
6.7% |
| Pneumocystis Jiroveci Pneumonia |
6.7% |
| Gastrointestinal Mucosal Disorder |
5.0% |
| Radiation Mucositis |
5.0% |
| Fistula |
3.3% |
| General Physical Health Deterioration |
3.3% |
| Metastases To Skin |
3.3% |
| Pulmonary Embolism |
3.3% |
| Pyrexia |
3.3% |
| Renal Failure |
3.3% |
| Stomatitis |
3.3% |
| Weight Decreased |
3.3% |
| Hyponatraemia |
1.7% |
| Interstitial Lung Disease |
1.7% |
| Lipoatrophy |
1.7% |
| Metastases To Central Nervous System |
1.7% |
|
| Concomitant |
| Breast Cancer |
37.8% |
| Breast Cancer Metastatic |
26.8% |
| Metastases To Liver |
11.0% |
| Metastases To Central Nervous System |
8.5% |
| Epilepsy |
4.9% |
| Asthma |
2.4% |
| Drug Use For Unknown Indication |
2.4% |
| Breast Neoplasm |
1.2% |
| Cancer Pain |
1.2% |
| Hepatic Neoplasm Malignant |
1.2% |
| Hypercholesterolaemia |
1.2% |
| Inflammatory Carcinoma Of The Breast |
1.2% |
|
| Disease Progression |
14.3% |
| Dihydropyrimidine Dehydrogenase Deficiency |
10.7% |
| Metastases To Central Nervous System |
10.7% |
| Drug Toxicity |
7.1% |
| Pulmonary Embolism |
7.1% |
| Vertigo |
7.1% |
| Vomiting |
7.1% |
| Anaphylactic Shock |
3.6% |
| Asthma |
3.6% |
| Diabetes Mellitus |
3.6% |
| Disease Recurrence |
3.6% |
| Excessive Granulation Tissue |
3.6% |
| Neoplasm Malignant |
3.6% |
| Osteonecrosis |
3.6% |
| Palmar-plantar Erythrodysaesthesia Syndrome |
3.6% |
| Upper Respiratory Tract Infection |
3.6% |
| Urticaria |
3.6% |
|
